Stocks and Investing
Stocks and Investing
Tue, March 21, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Decreased Target to $66 on, Mar 21st, 2023
Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $79 to $66 on, Mar 21st, 2023.
Raghuram has made no other calls on BTAI in the last 4 months.
There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 2 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $22 on, Friday, March 10th, 2023
- Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $26 on, Thursday, January 26th, 2023
This is the rating of the analyst that currently disagrees with Raghuram
- Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $38 on, Wednesday, February 8th, 2023
Contributing Sources